Initial Public Offering, Manufacturing and Negotiation

Why Aren’t More Tire Dealerships Going Public?

Focus Investment Banking

FEBRUARY 25, 2024

First, there’s the ability to raise substantial capital by issuing shares to the public in an initial public offering (IPO), as well as secondary offerings. Lastly, going public is a liquidity event for the founders and early investors, allowing them to cash in on their success.

Private Equity

Private Equity IPO Equities Public Trading

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. billion acquisition of Catalent, a leader in contract manufacturing for cell and gene therapies, stands out as the largest healthcare deal of 2024.

M&A

M&A Mergers and Acquisitions Pharmaceutical Acquisitions

Investment Banking Today

Why Aren’t More Tire Dealerships Going Public?

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Stay Connected